Selcaxen is identified for this website as a product containing 40 mg of selpercatinib.
Product identity
| Product characteristic | Information |
|---|---|
| Product | Selcaxen |
| Active ingredient | Selpercatinib |
| Stated strength | 40 mg |
| Drug class | Selective RET kinase inhibitor |
| Therapeutic category | Targeted anticancer medicine |
| Route | Oral, subject to product documentation |
| Reference product | RETEVMO |
| Original development program | Loxo Oncology / Eli Lilly |
| Selcaxen manufacturer | Everest Pharmaceuticals Ltd. |
Active ingredient
Selpercatinib inhibits RET kinase signaling. Its therapeutic use depends on the presence of a clinically relevant RET fusion or mutation, depending on the cancer being treated.
Reference product
RETEVMO is the established selpercatinib product in the United States. The medicine received initial U.S. approval in 2020.
Product distinction
Selcaxen should be distinguished from:
- Selpercatinib, the active pharmaceutical ingredient.
- RETEVMO, the reference/commercial product.
- The company that developed selpercatinib.
- The manufacturer of the specific Selcaxen product.
- Any distributor or supplier.
Therapeutic context
Selpercatinib is used for selected RET-driven cancers, including certain RET fusion-positive lung, thyroid and other solid tumors and RET-mutant medullary thyroid cancer.
Safety
Important risks include hepatotoxicity, ILD/pneumonitis, hypertension, QT prolongation, hemorrhage, hypersensitivity and tumor lysis syndrome.
Product verification
Selcaxen’s manufacturer, packaging and authorization should be checked against official documentation before use.